Lori Anne Kunkel - 30 Oct 2026 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
03 Nov 2026, 17:21:24 UTC
Prior SEC filing
08 Jul 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Ben Hohl, by power of attorney
Filing notes and source

Key filing fact

Lori Anne Kunkel filed Form 4 for Enliven Therapeutics, Inc. (ELVN) on 03 Nov 2026.

Key facts

  • This page summarizes Lori Anne Kunkel's Form 4 filing for Enliven Therapeutics, Inc. (ELVN).
  • 4 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 03 Nov 2026, 17:21.

Change

  • Previous filing in this sequence was filed on 08 Jul 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001536368 Primary reporting owner

Kunkel Lori Anne

Relationship
Director
Address
C/O ENLIVEN THERAPEUTICS, INC., 205 PARK ROAD, BURLINGAME
Signature
/s/ Ben Hohl, by power of attorney
Signature date
03 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELVN transaction

Common Stock

Options Exercise

Transaction value
Shares
+3,741
Change %
+8.9%
Price
$1.12*
Shares after
45,625
Date
30 Oct 2026
Ownership
Direct
ELVN transaction

Common Stock

Options Exercise

Transaction value
Shares
+7,300
Change %
+16%
Price
$18.30*
Shares after
52,925
Date
30 Oct 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELVN transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-3,741
Change %
-100%
Price
$0.000000*
Shares after
0
Date
30 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,741
Exercise price
$1.12
Footnotes
F1
ELVN transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-7,300
Change %
-19%
Price
$0.000000*
Shares after
30,582
Date
30 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,300
Exercise price
$18.30
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Footnote F2

The option, originally for 37,882 shares, of which 7,300 shares have been exercised, vests as to 1/36th of the shares on May 8, 2024 and each month thereafter, subject to the Reporting Person continuing as an outside director through each such date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .